A new oral drug for pancreatic cancer, daraxonrasib, has stopped tumor growth in more than 90% of patients in a clinical trial, offering fresh hope against one of the deadliest forms of cancer. The results, presented at an international cancer conference this week, show that the pill, when combined with standard chemotherapy, not only halted disease progression but also shrank tumors in a majority of participants.
According to data shared at the EORTC-NCI-AACR Symposium in Barcelona, the phase 1/2 trial tested daraxonrasib alongside two standard chemotherapy drugs, gemcitabine and nab-paclitaxel. Among 61 patients with advanced pancreatic cancer, tumors shrank in 60.7% of cases, and in 8.2% of patients, the tumors became completely undetectable on scans. Overall, tumor growth was stopped in 90.2% of participants, with the average duration of disease control lasting over a year before any signs of progression returned.
Daraxonrasib targets a mutated protein called KRAS, which is present in the vast majority of pancreatic cancers and acts as a “stuck accelerator,” causing cancer cells to keep growing. The drug is designed to switch off this growth signal, a feat that researchers previously considered nearly impossible to achieve with medication, according to oncologists cited by Fox News and the BBC.
The clinical trial results have been described by doctors as a “massive breakthrough” for pancreatic cancer, which is notorious for its resistance to existing treatments and typically has a very poor prognosis. Dr. Wungki Park, an oncologist involved in the study, told reporters that the findings represent “the closest to cure” seen so far for this disease, though he and other experts caution that more research is needed to determine how long the benefits will last and whether it can be considered a cure.
The U.S. Food and Drug Administration approved daraxonrasib as a once-daily pill for certain groups of pancreatic cancer patients in September, with the European Commission following suit this week, according to multiple sources. The drug is now being evaluated in a global Phase III trial to compare its effectiveness alone and in combination with chemotherapy versus chemotherapy alone.
Pancreatic cancer is the third-deadliest cancer worldwide, with a five-year survival rate of less than 10%. Most patients are diagnosed at an advanced stage, and standard treatments such as chemotherapy, radiation, and immunotherapy have had limited success. The emergence of a targeted therapy that can halt tumor growth in the majority of patients marks a significant advance, according to Cancer Research UK, which called the results “the biggest leap forward in decades” for patients with this disease.
In addition to its impact on pancreatic cancer, early research suggests that daraxonrasib may also have potential in treating other cancers driven by similar mutations, including lung, liver, and cervical cancers. However, further clinical trials will be required to confirm its effectiveness in these settings.
Patients in the trial were followed for a median of 18 months, with those receiving daraxonrasib and chemotherapy experiencing a median survival time of 13.2 months—nearly double that of patients treated with chemotherapy alone, according to figures reported by the Financial Times and other outlets.
Why it matters
The trial results mark a turning point for pancreatic cancer treatment, a field where progress has been slow and survival rates have remained stubbornly low for decades. The ability of daraxonrasib to halt tumor growth in over 90% of patients and shrink tumors in more than 60% offers new hope to those facing a disease that is often diagnosed too late for curative surgery.
Experts from Memorial Sloan Kettering Cancer Center and Cancer Research UK have highlighted the significance of targeting the KRAS mutation, which drives the majority of pancreatic cancers. Until now, this mutation has been considered “undruggable,” and the success of daraxonrasib could pave the way for similar therapies in other hard-to-treat cancers.
With regulatory approvals already granted in the US and Europe, and a global Phase III trial underway, the focus now turns to confirming the drug’s long-term benefits and expanding its use to a wider group of patients. The results are being closely watched by oncologists, patient advocacy groups, and pharmaceutical companies seeking to address one of the most challenging cancers in modern medicine.
The image accompanying this article is an AI-generated illustrative depiction inspired by the actual scene of the event.































